Oncology Adjuvants Market - Top Companies and Manufacturers

In the News

• The benefit and feasibility of a novel approach to surgical treatment in NSCLC was demonstrated by the AEGEAN trial in June 2021. In patients with non-small cell lung cancer, combining neoadjuvant durvalumab with platinum-based chemotherapy, taken after by curative-intent surgery and adjuvant durvalumab progressed antitumor action and diminished repeat chance. In addition, perioperative durvalumab increased the rate of pathologic complete response by 12.9% when compared to placebo.
• Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a single agent, for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB, II, or IIIA non-small cell lung cancer.